Retrophin Revenue and Competitors
Estimated Revenue & Valuation
- Retrophin's estimated annual revenue is currently $11.6M per year.
- Retrophin received $149.5M in venture funding in March 2015. 0
- Retrophin's total funding is $317.5M.
Retrophin Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Retrophin?
We are a biopharmaceutical company (RTRX) dedicated to identifying, developing and delivering life-changing therapies to people living with rare diseases. With our promising pipeline, commercial portfolio and more than 180 team members worldwide, we are a thriving and patient-centric company striving to become a leader in the rare disease community. Giving patients a chance and providing hope is what drives us. Our number one priority will always be the patients we serve. Our approach centers on our pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Our R&D efforts are supported by growing revenues from our portfolio of three commercial products. Thank you for visiting our LinkedIn profile. Please read our community guidelines to understand how we manage our social media engagement: retrophin.com/community-guidelineskeywords:Biotechnology, Healthcare
Number of Employees
Employee Growth %
Retrophin, LLC, a New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, has completed its $4m Series A financing. The round was led by MSMB Capital, with participation from several current and former senior executives at g ...
[Corrected, 8/23/19, see below] Retrophin, the drug developer founded by jailed former biotech executive Martin Shkreli, has failed its first big ...
Retrophin will host a conference call and webcast today, Thursday, August 22, 2019 at 8:30 a.m. ET to discuss the FORT Study results.
Shares of the orphan drug specialist Retrophin (NASDAQ:RTRX) are down by 25.3% as of 12:44 p.m. EDT today. The culprit? Retrophin's ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|2014-07-03||$91.0M||Undisclosed||Athyrium Capital Management||Article|